HTG Molecular Diagnostics

HTG Molecular Diagnostics Equity

The The Equity of HTG Molecular Diagnostics (HTGMQ) as of Nov 4, 2026 is 5.39 M USD. In the previous year, The Equity was 10.40 M USD — a change of -48.16% (lower).

Equity

5.39 MUSD

YoY

-48.16%

Last updated:

In 2022, HTG Molecular Diagnostics's equity was 5.39 M USD, a -48.16% increase from the 10.40 M USD equity in the previous year.

The HTG Molecular Diagnostics Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2015
16.89 M USD
Jan 1, 2016
-5.59 M USD
Jan 1, 2017
-3.06 M USD
Jan 1, 2018
21.09 M USD
Jan 1, 2019
23.97 M USD
Jan 1, 2020
14.48 M USD
Jan 1, 2021
10.40 M USD
Jan 1, 2022
5.39 M USD
The HTG Molecular Diagnostics Equity history
YEAREquityYoY
5.39 MUSD-48.16%
10.40 MUSD-28.20%
14.48 MUSD-39.57%
23.97 MUSD+13.64%
21.09 MUSD-789.39%
-3.06 MUSD-45.30%
-5.59 MUSD-133.11%
16.89 MUSD-170.27%
-24.04 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HTG Molecular Diagnostics Stock analysis

What does HTG Molecular Diagnostics do? HTG Molecular Diagnostics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing HTG Molecular Diagnostics's Equity

HTG Molecular Diagnostics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding HTG Molecular Diagnostics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating HTG Molecular Diagnostics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

HTG Molecular Diagnostics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in HTG Molecular Diagnostics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about HTG Molecular Diagnostics stock

The Equity of HTG Molecular Diagnostics is 5.39 M USD in 2022.

The Equity of HTG Molecular Diagnostics changed from 10.40 M USD to 5.39 M USD, representing a -48.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity HTG Molecular Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's HTG Molecular Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — HTG Molecular Diagnostics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — HTG Molecular Diagnostics